| 1 |
Wenstrom KD. Evaluation of Down's syndrome screening strategies[J]. Semin Perinatol, 2005, 29(4):219-224.
|
| 2 |
Christiansen M, Sorensen TL, Norgaard-Pedersen B. Human placental lactogen is a first－trimester maternal serum marker of Down's syndrome[J]. Prenat Diagn, 2007, 27(1):1-5.
|
| 3 |
Baviera G, Carbone C, Corrado F, et al. Placental growth hormone in Down's syndrome screening [J]. J Matern Fetal Neonatal Med, 2004, 16(4):241-243.
|
| 4 |
Laigaard J, Spencer K, Christiansen M, et al. ADAM 12 as a first－trimester maternal serum marker in screening for Down's syndrome[J]. Prenat Diagn, 2006, 26(10):973-979.
|
| 5 |
Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: The results of the serum, urine and ultrasound screening study (SURUSS) [J]. Health J Med Screen, 2003, 10(2):56-104.
|
| 6 |
Joseph E, Brien O, Dvorin E, et al. Differential increases in AFP, HCG, and uE3 in twin pregnancies: Impact on attempts to quantify Down syndrome screening calculations [J]. Am J Med Genet, 1997, 73(2):109-112.
|
| 7 |
Ohnishi J, Ohnishi E, Shibuya H, et al. Functions for proteinases in the ovulatory process [J]. Biochin Biophys Acta, 2005, 1751(1):95-109.
|
| 8 |
Odibo AO, Sehdew HM, Stamilio DM, et al. Evaluating the thresholds of abnormal second trimester multiple marker screening tests associated with intrauterine growth restriction [J]. Am J Perinatol, 2006, 23(6):363-367.
|
| 9 |
Celentano C, Guanciali-Franchi PE, Liberati M, et al. Lack of correlation between elevated maternal serum HCG during second－trimester biochemical screening and fetal enital anomaly[J]. Prenat Diagn, 2005, 25(3):220-222.
|
| 10 |
Goetzl L, Krantz D, Simpson JL, et al. Pregnancy－associated plasma protein A, free β－hCG, nuchal translucency, and risk of pregnancy loss [J]. Obstet Gynecol, 2004, 104(1):30-36.
|
| 11 |
Malone FD, Canick JA, Ball RB, et al. First－trimester or second－trimester screening or both for Down's syndrome[J]. N Engl J Med, 2005, 353(19):2001-2011.
|
| 12 |
Pandya PP, Snijders RJ, Johnson SP, et al. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10－14 weeks of gestation [J]. Br J Obstet Gynaecol, 1995, 102(10):957-962.
|
| 13 |
Thilaqanathan B, Slack A, Wathen NC. Effect of first－trimester nuchal translucency on second－trimester maternal serum biochemical screening for Down's syndrome[J]. Ultras Obstet Gynecol, 1997, 10(4):261-264.
|
| 14 |
Pinette MG, Blackstone J, Pan Y, et al. Measurement of fetal nasal width by ultrasonography [J]．Am J Obstet Gynecol, 1997, 177(4):842-845.
|
| 15 |
Verdin SM, Braethwaite JM, Spencer K, et al. Prenatal diagnosis of trysome 21 in monozygotic twins with increase nuchal translucenly and abnormal serum biolchermistry [J]. Fetal Diagn Ther, 1997, 12(3):153-155.
|
| 16 |
Lockrow J, Prakasam A, Huang P, et al. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model [J]. Exp Neurol, 2009, 216(2):278-289.
|
| 17 |
Moldrich RX, Dauphinot L, Laffaire J, et al. Down syndrome gene dosage imbalance on cerebellum development[J]. Prog Neurobiol, 2007, 82(2):87-94.
|